NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings is moving into diagnostics for orphan diseases and today announced it has completed a $5.5 million fundraising round.

The firm's diagnostics division holds the rights to MSPrecise, a proprietary next-generation sequencing assay for identifying patients with relapsing-remitting multiple sclerosis at first clinical presentation; an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer's disease; and the intellectual property for NuroPro, a Parkinson's disease diagnostic test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.